What I Tell My Patients About...

Role of CDK4/6 Inhibitors in ER-Positive Localized Breast Cancer

• Outcomes with historical treatment approaches for high-risk ER-positive localized breast cancer
• Biologic rationale for the assessment of CDK4/6 inhibitors as adjuvant therapy for patients with high-risk ER-positive localized breast cancer
• Key efficacy and safety findings with the addition of abemaciclib to standard adjuvant hormonal therapy for patients with ER-positive, HER2-negative breast cancer at high risk of recurrence; identification of appropriate candidates for this strategy
• Other ongoing studies evaluating CDK4/6 inhibitors as a component of neoadjuvant or adjuvant therapy

Selection and Sequencing of Therapy for ER-Positive Metastatic Breast Cancer (mBC)

• Long-term follow-up data and overall survival findings with CDK4/6 inhibitors for patients with ER-positive mBC
• Factors in the selection of a CDK4/6 inhibitor and an endocrine partner for first-line treatment
• Spectrum, frequency and management of clinically relevant hematologic and nonhematologic toxicities with CDK4/6 inhibitors
• Proposed mechanisms of resistance to CDK4/6 inhibition; prevalence of PIK3CA mutations in ER-positive mBC
• Published research findings with alpelisib/fulvestrant for patients with ER-positive mBC and PIK3CA mutations; optimal incorporation in current management algorithms
• Incidence and severity of common toxicities associated with alpelisib; appropriate monitoring, prevention and management strategies

Selection of Neoadjuvant and Adjuvant Therapy for HER2-Positive Localized Breast Cancer

• Clinical factors in the decision to administer neoadjuvant and adjuvant systemic treatment to patients with HER2-positive localized breast cancer; selection of appropriate regimens
• Feasibility of chemotherapy de-escalation in the setting of dual HER2 blockade for patients with localized disease
• Key data supporting the use of adjuvant T-DM1 for HER2-positive breast cancer; role for patients with residual disease after neoadjuvant therapy and in other populations
• Patient selection for and clinical factors guiding the use of neratinib as extended-adjuvant therapy; improvement in the rates of CNS recurrence with neratinib

Selection and Sequencing of Available Therapies for HER2-Positive mBC

• Patient- and disease-specific factors affecting decision-making in this setting
• Published data from pivotal studies of tucatinib/trastuzumab/capecitabine, trastuzumab deruxtecan (T-DXd) and neratinib/capecitabine for HER2-positive mBC
• Comparative efficacy observed with T-DXd versus T-DM1 for patients with HER2-positive mBC previously treated with trastuzumab and a taxane; implications for therapeutic sequencing
• Key considerations in the clinical care of patients with HER2-positive brain metastases

Tolerability of HER2-Targeted Therapies in Breast Cancer

• Similarities and differences among the available HER2-targeted TKIs (eg, neratinib, tucatinib, lapatinib) and correlation with the incidence and severity of class-related and agent-specific toxicities
• Frequency and severity of gastrointestinal (GI) side effects with HER2-targeted TKIs (eg, diarrhea, vomiting)
• Dose escalation and other available approaches to mitigate neratinib-associated GI toxicities
• Strategies to manage T-DXd-associated interstitial lung disease/pneumonitis; indications for restarting T-DXd after resolution of symptoms
• Spectrum, incidence, severity and management of other toxicities reported with T-DXd

Role of PARP Inhibitors in the Management of Breast Cancer

• Frequency and clinical significance of BRCA and other DNA damage repair pathway mutations in breast cancer
• Mechanism of antitumor activity of PARP inhibitors in patients with breast cancer with BRCA mutations; similarities and differences between olaparib and talazoparib
• Key findings with adjuvant olaparib for patients with germline BRCA1/2 mutations and high-risk HER2-negative breast cancer; implications for genetic testing and disease management
• Long-term data guiding the optimal use of PARP inhibitors for patients with HER2-negative mBC and germline BRCA mutations
• Incidence, timing, severity and management of common class- and agent-specific toxicities associated with PARP inhibitors for breast cancer

Clinical Utility of Immune Checkpoint Inhibitor Therapy for Triple-Negative Breast Cancer (TNBC)

• Event-free survival advantage observed with neoadjuvant pembrolizumab combined with chemotherapy and continued as a single agent after surgery for patients with high-risk localized TNBC
• Selection of appropriate patients with high-risk localized TNBC for (neo)adjuvant pembrolizumab therapy
• Phase III data sets evaluating anti-PD-1/PD-L1 antibodies in combination with chemotherapy for patients with previously untreated PD-L1-positive metastatic TNBC (mTNBC); current role in clinical practice
• Pathophysiology, incidence and spectrum of immune-mediated and other adverse events observed with anti-PD-1/PD-L1 antibodies
• Optimal monitoring and management paradigm for immune-related and other adverse events with immune checkpoint inhibitors for TNBC

Use of Sacituzumab Govitecan in mTNBC

• Mechanism of antitumor activity of sacituzumab govitecan in patients with breast cancer
• Published research evidence comparing sacituzumab govitecan to physician’s choice of chemotherapy for relapsed/refractory mTNBC
• Optimal integration of sacituzumab govitecan into current mTNBC management algorithms
• Ongoing research evaluating sacituzumab govitecan in earlier lines of therapy, combined with other systemic agents or in different patient populations
• Incidence, time to onset and management of diarrhea reported with sacituzumab govitecan
• Appropriate monitoring and management approaches for other common sacituzumab govitecan-related adverse events

Thank you for your interest in our NCPD program taking place in Anaheim, CA. At this time online preregistration for in-person is closed for this event. ONSITE REGISTRATION SEATING WILL BE BASED UPON AVAILABILTY - ON A FIRST COME FIRST SERVCE BASIS. Our Onsite Registration Desk will be open at 5:30 PM Pacific Time on Friday, April 29th. If you are interested in attending, please visit our registration desk located outside the Grand Ballroom E-K (Lobby Level) of the Anaheim Marriott hotel (700 West Convention Way) which is within walking distance (0.2 miles) of the Anaheim Convention Center.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

Please note, onsite registration does not guarantee meal service which will be based on availability.